Folia Microbiologica

, Volume 60, Issue 4, pp 351–356 | Cite as

In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin

  • Ebru EvrenEmail author
  • Erkan Yurtcu


Limited treatment options in infectious diseases caused by resistant microorganisms created the need to search new approaches. Several herbal extracts are studied for their enormous therapeutic potential. Silymarin extract, from Silybum marianum (milk thistle), is an old and a new remedy for this goal. The purpose of this study is to evaluate the antibacterial and antiadherent effects of silymarin besides biofilm viability activity on standard bacterial strains. Minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC), antiadherent/antibiofilm activity, and effects on biofilm viability of silymarin were evaluated against standard bacterial strains. MIC values were observed between 60 and >241 μg/mL (0.25–>1 mmol/L). Gram-positive bacteria were inhibited at concentrations between 60 and 120 μg/mL. Gram-negative bacteria were not inhibited by the silymarin concentrations included in this study. MBC values for Gram-positive bacteria were greater than 241 μg/mL. Adherence/biofilm formations were decreased to 15 μg/mL silymarin concentration when compared with silymarin-untreated group. Silymarin reduced the biofilm viabilities to 13 and 46 % at 1 and 0.5 mmol/L concentrations, respectively. We demonstrated that silymarin shows antibacterial and antiadherent/antibiofilm activity against certain standard bacterial strains which may be beneficial when used as a dietary supplement or a drug.


Minimal Inhibitory Concentration American Type Culture Collection Silymarin Minimal Bactericidal Concentration Silibinin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was approved by Baskent University Institutional Review Board (Project no: 14/09) and supported by Baskent University Research Fund.

Conflict of interest

The authors declare that they have no competing interests.


  1. Abenavoli L, Capasso R, Milic N, Capasso F (2010) Milk thistle in liver diseases: past, present, future. Phytother Res 24:1423–1432CrossRefPubMedGoogle Scholar
  2. Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R (2003) Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 22:271–82CrossRefGoogle Scholar
  3. Alviano DS, Barreto AL, Dias Fde A, Rodrigues Ide A, Rosa Mdo S, Alviano CS, Soares RM (2012) Conventional therapy and promising plant-derived compounds against trypanosomatid parasites. Front Microbiol 6(3):283Google Scholar
  4. Bakkali F, Averbeck S, Averbeck D, Idaomar M (2008) Biological effects of essential oils—a review. Food Chem Toxicol 46(2):446–75CrossRefPubMedGoogle Scholar
  5. Baylan O (2010) Fosfomycin: past, present and future. Mikrobiyol Bul 44:311–321PubMedGoogle Scholar
  6. Bibi Y, Nisa S, Chaudhary FM, Zia M (2011) Antibacterial activity of some selected medicinal plants of Pakistan. BMC Complement Altern Med 11:52CrossRefPubMedCentralPubMedGoogle Scholar
  7. Bjarnsholt T (2013) The role of bacterial biofilms in chronic infections. APMIS Suppl 136:1–51. doi: 10.1111/apm.12099 CrossRefPubMedGoogle Scholar
  8. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37(6):1771–6PubMedCentralPubMedGoogle Scholar
  9. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF, Melton DM, Beachey EH (1985) Adherence of coagulase negative staphylococci to plastic tissue cultures: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 22:996–1006PubMedCentralPubMedGoogle Scholar
  10. Clinical and Laboratory Standards Institute (CLSI) (2012) Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement M100-S22. CLSI, WayneGoogle Scholar
  11. Coenye T, Nelis HJ (2010) In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods 83:89–105CrossRefPubMedGoogle Scholar
  12. Cushnie TP, Lamb AJ (2005) Antimicrobial activity of flavonoids. Int J Antimicrob Agents 26(5):343–56CrossRefPubMedGoogle Scholar
  13. Donlan RM (2001) Biofilm formation: a clinically relevant microbiological process. Healthcare Epidemiology CID 33:1387–1392Google Scholar
  14. Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Healthcare Epidemiology CID 52:1039–1045Google Scholar
  15. Edwards-Jones V (2013) Alternative antimicrobial approaches to fighting multi-drug resistant infections. In: Rai M, Kon K (eds) Frightening multidrug resistance with herbal extracts, essential oils and their components. Elsevier, USA, pp 1–9CrossRefGoogle Scholar
  16. Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM (2007) A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25:139–146CrossRefPubMedGoogle Scholar
  17. Gharagozloo M, Javid EN, Rezaei A, Mousavizadeh K (2013) Silymarin inhibits cell cycle progression and mTOR activity in activated human T cells: therapeutic implications for autoimmune diseases. Basic Clin Pharmacol Toxicol 112(4):251–6CrossRefPubMedGoogle Scholar
  18. Ghosh A, Ghosh T, Jain S (2010) Silymarin-a review on the pharmacodynamics and bioavailability enhancement approaches. J Pharm Sci Tech 2:348–355Google Scholar
  19. Gordon A, Hobbs DA, Bowden DS, Bailey MJ, Mitchell J, Francis AJ, Roberts SK (2006) Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 21:275–280CrossRefPubMedGoogle Scholar
  20. Hall MR, McGillicuddy E, Kaplan LJ (2014) Biofilm: basic principles, pathophysiology, and implications for clinicians. Surg Infect (Larchmt) 15(1):1–7CrossRefGoogle Scholar
  21. Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M (2011) Evaluation of different detection methods of biofilm formation in the clinical isolates. Braz J Infect Dis 15:305–311CrossRefPubMedGoogle Scholar
  22. Høiby N, Bjarnsholt T, Moser C, Bassi GL, Coenye T, Donelli G, Hall-Stoodley L, Holá V, Imbert C, Kirketerp-Møller K, Lebeaux D, Oliver A, Ullmann AJ, Williams C (2015) ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. doi: 10.1016/j.cmi.2014.10.024 PubMedGoogle Scholar
  23. Ji-Lu S, Shao-Kang Z, Jing-Yu C, Bei-Zhong H (2012) Efficacy of acidic and basic electrolyzed water in eradicating Staphylococcus aureus biofilm. Can J Microbiol 58:448–454CrossRefGoogle Scholar
  24. Kang HK, Kim HY, Cha JD (2011) Synergistic effects between silibinin and antibiotics on methicillin-resistant Staphylococcus aureus isolated from clinical specimens. Biothecnol J 13:397–408Google Scholar
  25. Lahlah ZF, Meziani M, Maza A (2012) Silymarin natural antimicrobial agent extracted from Silybum marianum. Journal Academia 2:164–169Google Scholar
  26. Lee DG, Kim HK, Park Y, Park SC, Woo ER, Jeong HG, Hahm KS (2003) Gram positive bacteria specific properties of silybin derived from Silbum marianum. Arch Pharm Res 26:597–600CrossRefPubMedGoogle Scholar
  27. Lee YS, Jang KS, Cha JD (2012) Synergistic antibacterial effect between silibinin and antibiotics in oral bacteria. J Biomed Biotechnol 2012:618081. doi: 10.1155/2012/618081 PubMedCentralPubMedGoogle Scholar
  28. Lucey MR, Mathurin P, Morgan TR (2009) Alcoholic hepatitis. N Engl J Med 360:2758–69CrossRefPubMedGoogle Scholar
  29. Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH (2010) Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 107(13):5995–9CrossRefPubMedCentralPubMedGoogle Scholar
  30. Polyak SJ, Ferenci P, Pawlotsky JM (2013) Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology 57:1262–1271CrossRefPubMedCentralPubMedGoogle Scholar
  31. Post-White J, Ladas EJ, Kelly KM (2007) Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 6:104–109CrossRefPubMedGoogle Scholar
  32. Ramasamy K, Agarwal R (2008) Multitargeted therapy of cancer by silymarin. Cancer Lett 8:352–362CrossRefGoogle Scholar
  33. Sanchez-Sampedro A, Kim HK, Choi YH, Verpoorte R, Corchete P (2007) Metabolomic alterations in elicitor treated Silybum marianum suspension cultures monitored by nuclear magnetic resonance spectroscopy. J Biotechnol 130:133–142CrossRefPubMedGoogle Scholar
  34. Simánek V, Kren V, Ulrichová J, Vicar J, Cvak L (2000) Silymarin: what is in the name…? An appeal for a change of editorial policy. Hepatology 32(2):442–4CrossRefPubMedGoogle Scholar
  35. Stepanovic S, Vukovic D, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40(2):175–9CrossRefPubMedGoogle Scholar
  36. Stoddart MJ (2011) Cell viability assays: introduction. Methods Mol Biol 740:1–6PubMedGoogle Scholar
  37. Tamayo C, Diamond S (2007) Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.]gaertn.). Integr Cancer Ther 6:146–157CrossRefPubMedGoogle Scholar
  38. Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, Pécheur EI, Graf TN, Oberlies NH, Lohmann V, Cao F, Tavis JE, Polyak SJ (2010) Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 51:1912–1921CrossRefPubMedCentralPubMedGoogle Scholar
  39. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rózalska B (2005) Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol 54(3):191–200PubMedGoogle Scholar
  40. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rozalska B (2006) Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin. Folia Microbiol 51:381–386CrossRefGoogle Scholar
  41. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, Zhang HY, Li YW (2013) Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis 32:657–669CrossRefPubMedGoogle Scholar
  42. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC (2008) Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36(1):65–72CrossRefPubMedGoogle Scholar

Copyright information

© Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i. 2015

Authors and Affiliations

  1. 1.Department of Medical Microbiology, Faculty of MedicineBaskent UniversityAnkaraTurkey
  2. 2.Department of Medical Biology, Faculty of MedicineBaskent UniversityAnkaraTurkey

Personalised recommendations